Skip to main content

Peer Review reports

From: The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity

Original Submission
6 Jul 2011 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
19 Jul 2011 Reviewed Reviewer Report - Sabine Hombach-Klonisch
1 Aug 2011 Reviewed Reviewer Report - Emilia Wiechec
16 Aug 2011 Author responded Author comments - Wieslawa Dragowska
Resubmission - Version 3
16 Aug 2011 Submitted Manuscript version 3
7 Sep 2011 Author responded Author comments - Wieslawa Dragowska
Resubmission - Version 4
7 Sep 2011 Submitted Manuscript version 4
Resubmission - Version 5
Submitted Manuscript version 5
20 Sep 2011 Author responded Author comments - Wieslawa Dragowska
Resubmission - Version 6
20 Sep 2011 Submitted Manuscript version 6
Publishing
1 Oct 2011 Editorially accepted
1 Oct 2011 Article published 10.1186/1471-2407-11-420

You can find further information about peer review here.

Back to article page